Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)

Authors

B. Thapa
N. Henderson
S. T. Tagawa
Clara Hwang, Henry Ford HealthFollow
A. O. Sokolova
M. A. Bilen
P. M. Coelho Barata
C. B. Nguyen
A. Tripathi
A. Ayanambakkam
L. S. Graham
Y. Zakharia
V. S. Koshkin
E. Heath
T. B. Dorff
A. J. Armstrong
R. R. McKay
A. S. Alva
M. Schweizer
D. Kilari

Recommended Citation

Thapa B, Henderson N, Tagawa ST, Hwang C, Sokolova AO, Bilen MA, Coelho Barata PM, Nguyen CB, Tripathi A, Ayanambakkam A, Graham LS, Zakharia Y, Koshkin VS, Heath E, Dorff TB, Armstrong AJ, McKay RR, Alva AS, Schweizer M, Kilari D. Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC). 2024; (S2):S991.

Document Type

Conference Proceeding

Publication Date

9-1-2024

Issue

S2

First Page

S991